Trial Profile

A Phase 1, Open-Label, Dose Escalation and Expansion Study of Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACM 005 (Primary)
Indications Bladder cancer; Head and neck cancer; Lung cancer; Renal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

22 Oct 2025 Results presented in the ACM Biolabs Media Release.
22 Oct 2025 Results presented in the ACM Biolabs Media Release.
22 Oct 2025 According to ACM Biolabs media release, 2 of 3 patients have been enrolled at the 0.25mg dose level.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com